3sbio, Inc. · HKEX:1530
3sbio — H1 2022 Earnings Presentation
43 slides from 3sbio's earnings presentation, Aug 25, 2022
Slide 1: 2022 Interim Results Presentation
2022 Interim Results Presentation Au g u s t 2 5 , 2 0 2 2
Slide 2: Disclaimer
Disclaimer This document has been prepared by 3SBio Inc. (the "Company") solely for selected recipients for information purposes only. You must read the terms, conditions, limitations, notifications, restrictions, acknowledgments and representations in the following (collectively, the "Terms") befor
Slide 3: Agenda
Agenda 01 02 03 04 05 Business R&D Financial 2022H1 Highlights Q&A Overview Review 3
Slide 4: Chairman, Director & CEO Dr. Jing LOU
Chairman, Director & CEO Dr. Jing LOU
Slide 5: 2022H1 Financial Highlights
2022H1 Financial Highlights Income proportions： Main Performance 2022H1 2021H1 YoY (RMB million) Biopharmaceuticals Revenue 3091.4 3,107.1 -0.5% Hair Healthcare Gross Profit 2565.0 2,587.1 -0.9% CDMO Others NI Attributable to Parent 954.5 898.9 6.2% 2021H1 Norm NI Attributable to Parent 993.6 929.8
Slide 6: 2022H1 Highlights
2022H1 Highlights 2022.01 The global rights of PD-1 on specific therapy were authorized to U.S. Syncromune Inc. 2022.01 Mandi Foam NDA was accepted for review 2022.05 Phase III clinical study of TPIAO in pediatric ITP achieved the pre-defined primary endpoint 2022.05 During the outbreak of COVID-19,
Slide 7: Chairman, Director & CEO Dr. Jing LOU
Chairman, Director & CEO Dr. Jing LOU
Slide 8: Business Ⅰ: Biopharmaceuticals
Business Ⅰ: Biopharmaceuticals
Slide 9: Core Products
Core Products Revenue of Core Products, 2022H1 Product Growth rate RMB million TPIAO 3.5% 258 366 39 68 429 Mandi rhEPO -1.9% 234 543 533 Cipterbin Yisaipu Yisaipu -45.5% rhEPO 1,521 1,575 Cipterbin 111.6% TPIAO 2021H1 2022H1 Mandi 42.0% 9
Slide 10: TPIAO- Exclusive Commercialized rhTPO
TPIAO- Exclusive Commercialized rhTPO Revenue of TPIAO, 2022H1 Top 1 market share 1 66% 1 market share in terms of sales, still tops the first position in rhTPO products RMB million 66.0% TPIAO YOY：3.5% 3,080 Product A (Class 2,763 Interleukin) 2,323 1,521 1,575 Product B (Class TPO-RA ) 2019 2020 2
Slide 11: TPIAO- Distinct Space for Stable Growth
TPIAO- Distinct Space for Stable Growth Persistent Replacement Anticipated Indication and Penetration Full Course Management Expansion • The number of hospitals • Chemotherapy-induced • Pediatric ITP: 13K patients /year3, covered>4000 Thrombocytopenia (CIT) was prepared to NDA submission • 27%1 of p
Slide 12: rhEPO- EPIAO & SEPO
rhEPO- EPIAO & SEPO Revenue of rhEPO, 2022H1 TOP 1 Market share 1 Two brands dominate 44.1% market share, preside Top 1 position in terms of EPO market share RMB million 44.1% EPIAO&SEPO YOY：-1.9% rhEPO A 1,120 974 rhEPO B 749 rhEPO C 543 533 rhEPO D Others 2019 2020 2021 2021H1 2022H1 12
Slide 13: rhEPO- Indications Contain Incremental Space
rhEPO- Indications Contain Incremental Space 36% 10% 30% 36% 10% 30% Penetration rate Treatment rate Growth rate 4 million+ CIA patients, Incremental space for 800K+ patients, Extremely low treatment penetration in low-tier 10% annual rate of growth rate of anemia market CKD Related Increment CIA Re
Slide 14: Yisaipu- Explore to Reform
Yisaipu- Explore to Reform Revenue of Yisaipu, 2022H1 Strategic RA：First-choice of combing with cDMRADs Targets AS：Preferred drug after diagnosed RMB million Patient centered service Optimize selling process, Strengthen patient management, excellent service support competitiveness Develop new formul
Slide 15: Cipterbin- Break Bottleneck, Embrace Growth
Cipterbin- Break Bottleneck, Embrace Growth Revenue of Cipterbin, 2022H1 First-to-market domestic anti-Her2 Ab National 863 Plan, National Great New Drug R&D Project, RMB million 1st Priority Review Drug; Launched in 2020 and listed on the NRDL, Break the monopoly of imported products in anti- YOY：1
Slide 16: Cipterbin- Break Bottleneck, Embrace Growth
Cipterbin- Break Bottleneck, Embrace Growth Release Release All-round improvement of Guideline Recommendation Subject Time market coverage HER2-positive advanced breast cancer H treatment sensitive drugs recommendations： Guideline position Primary Recommendations: (1) THP(IA); (2) TXH (2A) Be improv
Slide 17: Business II: Hair Healthcare
Business II: Hair Healthcare
Slide 18: Mandi – Effective & Reliable Hair Product
Mandi – Effective & Reliable Hair Product Revenue of Mandi, 2022H1 Top 1 Market Share RMB million 1 71.9% Market Share, secured top 1 minoxidil 1 YOY：42.0% 71.9% Mandi 602 Product A 368 366 Product B 250 258 others 2019 2020 2021 2021H1 2022H1 1. Data source：CPA 18
Slide 19: Mandi – 3 Channels Propel Sales Increase
Mandi – 3 Channels Propel Sales Increase Hospital Retail Pharmacy Ecommerce Platform Revenue Increase: Revenue Increase: Revenue Increase: ~7%YOY ~80%YOY ~39%YOY 16% of Revenue ~ ~31% of Revenue ~ 53% of Revenue 200 plus personnel 100 plus personnel Annually reached 20 million plus people, 2 million
Slide 20: Mandi- Build Product Matrix, Explore Vast Market
Mandi- Build Product Matrix, Explore Vast Market Mandi Mandi Foam 60/90mL Male monthly course Be available soon, fill hair- loss market for sensitive hair skin population 25 million Target Population Mandi Shampoo Mandi White Bottle 30mL Female monthly course Extend to scenes of life in 10 billion t
Slide 21: Business Ⅲ: CDMO
Business II: CDMO
Slide 22: CDMO- Global One-stop Service Platform
CDMO- Global One-stop Service Platform Revenue of CDMO Business, 2022H1 20+ 100% executing projects achievement rate RMB million 1 NDA CDE accepted, 100 million+ The first customers’ backlogs, YoY surged product succeeded to commercialization RMB million YOY：32% 106 111 2021H1 100 YOY：38.1% 2022H1 Y
Slide 23: CDMO- Competitive Edge
CDMO- Competitive Edge Type of Service 6 6 plants interconnected, flexible production system, serve the whole life cycle of drugs BsAb/ mAb multispecific Ab >50 Experience of 50+ internal and external IND projects Fusion protein Recombinant 15 months from DNA to IND on average 15M protein 0% failure
Slide 24: CDMO- Six Global Plants
CDMO- Six Global Plants Sirton, Italy Guojian, Group CDMO Map Formulations Clients include Mylan, Shanghai Biopharmaceuticals Sanofi and on Depend on Sunshine Guojian professional biopharmaceuticals Desen, Shenyang system, honored as Biopharmaceuticals Veteran in Biologics Initial stage 76K liters •
Slide 25: Chairman, Director & CEO Dr. Jing LOU
Chairman, Director & CEO Dr. Jing LOU
Slide 26: R&D Pipeline
R&D Pipeline Therapeutic Area Candidates Pre-clinical IND Phase I Phase II Phase III NDA 5 TPO-105 Pediatric ITP Pre-clinical TPO-106 CLDT SSS06 Long-acting rhEPO RD01 Long-acting rhEPO Nephrology SSS17 HIF inhibitor SSS20 Eltrombobag BE 7 SSS12 Cinacalcet hydrochloride ANDA IND& phase I SSS13 Sevel
Slide 27: 2022 H1 R&D Progress
2022 H1 R&D Progress Nephrology Auto-immune Dermatology • MN709 (Minoxidil foam) ） • TPO-105 (Pediatric ITP) phase III completed, • 301S TNFα-Fc R-protein NMPA accepted for review NMPA accepted for review, prepare NDA in preparations for on-site inspection • TPO-106 (CLDT) Phase Ib/II completed, • 6
Slide 28: Key Candidates: Nephrology Drug
Key Candidates: Nephrology Drug Remitch (Narfuraphine hydrochloride orally disintegrating tablets) First-line Drugs for Liver& Kidney Disease Pruritus Exclusive product，Focus on Millions of in Japan Guidelines Nephrology Patients’ Clinical Demands Uremic pruritus (UP) -2009 Chronic Liver Disease Pru
Slide 29: Key Candidates: Autoimmune Pipelines
Key Candidates: Autoimmune Pipelines Based on Clinical Demands for Pipeline strategy： Autoimmune & Inflammation Pipeline Pipelines Newly Indications Expansion， Indications Coverage Coverage: Construct FIC/BIC AD, Chronic 4.2% prevalence of Asthma in the population products Rhinosinusitis, Asthma, 01
Slide 30: Key Candidates: Anti-IL17A mAb (608)
Key Candidates: Anti-IL17A mAb (608) 608- Moderate-to-Severe Plaque Psoriasis Brand-new Amino Acid Higher Drug Effect than Peers, High Incidence Rate, Huge Market Size Sequence Targeting IL-17A Potential Best-in-class • 608 Ab adopts recombinant • The data of Phase II study showed that 80.6%, • ~0.4
Slide 31: Key Candidates: Anti-IL5 mAb (610)
Key Candidates: Anti-IL5 mAb (610) 610- Eosinophil Asthma Brand-new mAb Targeting IL-5, Good Safety and Significant High Incidence Rate, Huge Market Size Variable Region Sequences Drug Effect • Adopt recombinant DNA technology, new • Drug effectiveness: one dose • The article1 launch on the Lancet i
Slide 32: Key Candidates: Anti-IL4R mAb (611)
Key Candidates: Anti-IL4R mAb (611) 611-Moderate-to-Severe Atopic Dermatitis Brand-new Amino Acid Sequence Good Safety and Significant High Incidence Rate, Huge Market Size Targeting IL-4Rα Drug Effect • Recombinant humanized IgG4 mAb; • Good safety and tolerance, especially • Worldwide: High incide
Slide 33: Key Candidates: Anti-IL1β mAb (613)
Key Candidates: Anti-IL1β mAb (613) 613- Acute Gout Arthritis Brand-new mAb Targeting IL-1β Good Safety, Significant PK High Incidence Rate, Huge Clinical Demands Linear Relation • anti-IL1β humanized mAb adopt • Study on Chinese subjects demonstrate • Worldwide: the research based on Asian, Europea
Slide 34: International Cooperation
International Cooperation International R&D Collaboration International Registration /Clinical Trial Massachusetts U.S. Commercialized products registered abroad • TPO was acquired launching license from 9 countries while • Select candidates in tumor immunotherapy, 3SBio is responsible for registere
Slide 35: R&D Center and Platform
R&D Center and Platform Four Centers, Five Platforms --Cover All-process of R&D, Registration, Clinical trials, Manufacture Shenyang Shanghai Shenzhen Hangzhou center center center center BsAb & Multifunctional Fc Ab Maturity and Ab Selection Pre-clinical Animal Multispecific Ab Protein Optimization
Slide 36: Chief Financial Officer Mr. Fei WANG
Chief Financial Officer Mr. Fei WANG
Slide 37: Financial Analysis
Financial Analysis Revenue Gross Profit RMB billion RMB billion YoY：-0.9% YoY：-0.5% 6.4 5.3 5.6 5.3 4.4 4.5 3.1 3.1 2.6 2.6 2019 2020 2021 2021H1 2022H1 2019 2020 2021 2021H1 2022H1 NI Attributable to Parent NORM NI Attributable to Parent RMB million RMB million YoY ：6.2% YoY ：6.9% 1,651 1,727 1,392
Slide 38: Expense Management
Expense Management Selling and Distribution Expenses RMB billion Administrative Expenses YoY : 0.1% RMB million Equity Incentive Administrative 2.3 2.0 2.0 1.2 1.2 2019 2020 2021 2021H1 2022H1亿元 S&D Ratio 36.7% 36.1% 36.4% 37.1% 37.3% YoY : 16.5% R&D Costs 330 352 340 RMB mllion 151 185 YoY : -14.7%
Slide 39: Total Assets & Debt
Total Assets & Debt Total Assets RMB billion Debt Asset Ratio 40% Include CB 35.6% 20.6 Exclude CB 17.7 19.2 13.8 14.8 30.1% 29.7% 30% 2018 2019 2020 2021 2022H1 25.9% 23.7% 19.0% 18.8% 20% Net Assets 14.5% 12.0% 11.9% RMB billion 10% 0% 13.1 14.7 14.5 10.4 2018 2019 2020 2021 2022H1 8.9 2018 2019 2
Slide 40: Sublime CF Condition, Sufficient FCF
Sublime CF Condition, Sufficient FCF OCF Cash Equivalents (Financing Proceeds Included) RMB billion RMB billion YoY ：31.9% 6.5 1.9 5.0 4.5 1.6 1.3 1.1 2.6 0.8 1.9 2019 2020 2021 2021H1 2022H1 2018 2019 2020 2021 2022H1 40
Slide 41: Extremely Attractive Earnings
Extremely Attractive Earnings EPS (HKD) ROE HKD YoY : 11.4% 0.8 14.3% 13.0% 11.1% 9.5% 0.47 0.42 0.46 0.4 5.9% 2019 2020 2021 2021H1 2022H1 2018 2019 2020 2021 2022H1 41
Slide 42: Management
Business Overview fre Go » wu YY ey ae ey h, a Financial : UE dy Review
Slide 43: THANKS
THANKS 3SBio Inc. (1530.HK) Investor Relations ir@3sbio.com 珍 爱 生 命 · 关 注 生 存 · 创 造 生 活 CHERISH LIFE CARE FOR LIFE CREATE LIFE